Rezafungin Utilisation in Real Life—FungiScope Results From Europe and the United States Background Rezafungin, a novel echinocandin with once-weekly intravenous dosing, offers potential advantages for outpatient parenteral antifungal therapy (OPAT) in invasive candidiasis (IC). While c.....

Real-world data from EU & US: Rezafungin shows promise for invasive candidiasis in OPAT - effective, well tolerated, but access remains a barrier. Read the new FungiScope study 👉 onlinelibrary.wiley.com/doi/10.1111/...
#InvasiveFungalInfections #Rezafungin #FungiScope

ESCMID‐EFISG Survey on Diagnostic and Therapeutic Capacity for Invasive Fungal Infections in Belgium, the Netherlands, and Luxembourg: A Focus on High Azole Resistance Introduction Invasive fungal infections (IFI) are a major clinical challenge, particularly in immunocompromised patients, and are associated with high morbidity and mortality. With the increasing pr...

📊 New ESCMID-EFISG survey on IFI diagnostic & treatment capacity in Benelux shows gaps in access & azole resistance testing. Read the full study here: onlinelibrary.wiley.com/doi/10.1111/...
#InvasiveFungalInfections #AntifungalResistance #ESCMID